NasdaqGM:ARCT

Stock Analysis Report

Executive Summary

Arcturus Therapeutics Holdings Inc., an RNA medicines company, focuses on treatment of liver and respiratory diseases.

Snowflake

Fundamentals

Adequate balance sheet with weak fundamentals.

Risks

  • Arcturus Therapeutics has significant price volatility in the past 3 months.

Share Price & News

How has Arcturus Therapeutics's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

4.8%

NasdaqGM:ARCT

-0.5%

US Biotechs

-0.02%

US Market


1 Year Return

-25.0%

NasdaqGM:ARCT

-11.3%

US Biotechs

1.6%

US Market

ARCT underperformed the Biotechs industry which returned -8% over the past year.

ARCT underperformed the Market in United States of America which returned 0.6% over the past year.


Share holder returns

ARCTIndustryMarket
7 Day4.8%-0.5%-0.02%
30 Day18.4%-2.1%2.7%
90 Day38.8%-1.9%1.4%
1 Year-25.0%-25.0%-10.6%-11.3%3.8%1.6%
3 Yearn/a4.6%1.1%45.2%35.8%
5 Yearn/a1.9%-3.0%61.8%44.1%

Price Volatility Vs. Market

How volatile is Arcturus Therapeutics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Arcturus Therapeutics undervalued based on future cash flows and its price relative to the stock market?

11.71x

Price to Book (PB) ratio


Intrinsic Value Based on Future Cash Flows

Unable to calculate intrinsic value for Arcturus Therapeutics to establish if it is available at moderate discount.

Unable to calculate intrinsic value for Arcturus Therapeutics to establish if it is available at substantial discount.


Price Based on Earnings

Arcturus Therapeutics is loss making, we can't compare its value to the US Biotechs industry average.

Arcturus Therapeutics is loss making, we can't compare the value of its earnings to the United States of America market.


Price Based on Expected Growth

Unable to calculate PEG ratio for Arcturus Therapeutics, we can't assess if its growth is good value.


Price Based on Value of Assets

Arcturus Therapeutics is overvalued based on assets compared to the US Biotechs industry average.


Next Steps

Future Growth

How is Arcturus Therapeutics expected to perform in the next 1 to 3 years based on estimates from 4 analysts?

-3.4%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

Arcturus Therapeutics's revenue is expected to grow by 5.8% yearly, however this is not considered high growth (20% yearly).

Arcturus Therapeutics is not considered high growth as it is expected to be loss making for the next 1-3 years.

Arcturus Therapeutics's revenue growth is positive but not above the United States of America market average.

Unable to compare Arcturus Therapeutics's earnings growth to the United States of America market average as it is expected to be loss making during the next 1-3 years.

Unable to compare Arcturus Therapeutics's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.


Earnings per Share Growth Estimates


Future Return on Equity

Unable to establish if Arcturus Therapeutics will efficiently use shareholders’ funds in the future without estimates of Return on Equity.


Next Steps

Past Performance

How has Arcturus Therapeutics performed over the past 5 years?

-52.1%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Arcturus Therapeutics does not make a profit and their year on year earnings growth rate was negative over the past 5 years.

Unable to compare Arcturus Therapeutics's 1-year earnings growth to the 5-year average as it is not currently profitable.

Unable to compare Arcturus Therapeutics's 1-year growth to the US Biotechs industry average as it is not currently profitable.


Return on Equity

It is difficult to establish if Arcturus Therapeutics has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.


Return on Assets

It is difficult to establish if Arcturus Therapeutics has efficiently used its assets last year compared to the US Biotechs industry average (Return on Assets) as it is loss-making.


Return on Capital Employed

It is difficult to establish if Arcturus Therapeutics improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.


Next Steps

Financial Health

How is Arcturus Therapeutics's financial position?


Financial Position Analysis

Arcturus Therapeutics is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

Arcturus Therapeutics's cash and other short term assets cover its long term commitments.


Debt to Equity History and Analysis

Arcturus Therapeutics's level of debt (156.5%) compared to net worth is high (greater than 40%).

Unable to establish if Arcturus Therapeutics's debt level has increased without past 5-year debt data.


Balance Sheet

Low level of unsold assets.

Debt is covered by short term assets, assets are 3.7x debt.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Arcturus Therapeutics has sufficient cash runway for 1.2 years based on current free cash flow.

Arcturus Therapeutics has sufficient cash runway for 1.1 years if free cash flow continues to grow at historical rates of 105.9% each year.


Next Steps

Dividend

What is Arcturus Therapeutics's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate Arcturus Therapeutics's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate Arcturus Therapeutics's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as Arcturus Therapeutics has not reported any payouts.

Unable to verify if Arcturus Therapeutics's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as Arcturus Therapeutics has not reported any payouts.


Future Payout to Shareholders

Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.


Next Steps

Management

What is the CEO of Arcturus Therapeutics's salary, the management and board of directors tenure and is there insider trading?

0.8yrs

Average management tenure


CEO

Joseph Payne (47yo)

6.3yrs

Tenure

US$2,687,044

Compensation

Mr. Joseph E. Payne, M.Sc., founded Arcturus Therapeutics, Inc., in 2013 and serves as its President. Mr. Payne serves as Chief Executive Officer of Arcturus Therapeutics, Inc., since March 2013. Mr. Payne ...


CEO Compensation Analysis

Joseph's remuneration is higher than average for companies of similar size in United States of America.

Joseph's compensation has increased whilst company is loss making.


Management Age and Tenure

0.8yrs

Average Tenure

47yo

Average Age

The average tenure for the Arcturus Therapeutics management team is less than 2 years, this suggests a new team.


Board Age and Tenure

1.1yrs

Average Tenure

60yo

Average Age

The average tenure for the Arcturus Therapeutics board of directors is less than 3 years, this suggests a new board.


Insider Trading

No 3 month insider trading information.


Recent Insider Transactions

BuyUS$27,05420 Nov 18
Joseph Payne
EntityIndividual
Role
Chief Executive Officer
Founder
Shares4,000
Max PriceUS$6.76

Ownership Breakdown


Management Team

  • Andy Sassine (55yo)

    CFO & Director

    • Tenure: 1.1yrs
    • Compensation: US$640.14k
  • Joseph Payne (47yo)

    Founder

    • Tenure: 6.3yrs
    • Compensation: US$2.69m
  • Pad Chivukula (40yo)

    Founder

    • Tenure: 6.4yrs
    • Compensation: US$1.37m
  • Kevin Skol

    Senior Vice President of Business Development & Alliance Management

    • Tenure: 0.8yrs
  • Keith Kummerfeld

    VP of Finance & Corporate Controller

    • Tenure: 0.8yrs

Board Members

  • Peter Farrell (77yo)

    Chairman of the Board

    • Tenure: 1.1yrs
    • Compensation: US$183.66k
  • James Barlow (60yo)

    Independent Director

    • Tenure: 1.1yrs
    • Compensation: US$178.51k
  • Magda Marquet (60yo)

    Independent Director

    • Tenure: 1.1yrs
    • Compensation: US$176.80k
  • Andy Sassine (55yo)

    CFO & Director

    • Tenure: 1.1yrs
    • Compensation: US$640.14k
  • Joseph Payne (47yo)

    Founder

    • Tenure: 6.3yrs
    • Compensation: US$2.69m

Company Information

Arcturus Therapeutics Holdings Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Arcturus Therapeutics Holdings Inc.
  • Ticker: ARCT
  • Exchange: NasdaqGM
  • Founded: 2013
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$74.688m
  • Shares outstanding: 10.76m
  • Website: https://www.arcturusrx.com

Number of Employees


Location

  • Arcturus Therapeutics Holdings Inc.
  • 10628 Science Center Drive
  • Suite 250
  • San Diego
  • California
  • 92121
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
ARCTNasdaqGM (Nasdaq Global Market)YesOrdinary SharesUSUSDNov 2017

Biography

Arcturus Therapeutics Ltd., an RNA medicines company, focuses on treatment of liver and respiratory diseases. The company’s pipeline of RNA therapeutics include programs pursuing rare diseases, hepatitis B ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/06/14 00:58
End of Day Share Price2019/06/13 00:00
Earnings2019/03/31
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.